November 20, 2019 | English | عربي
Add to Twitter
Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
− Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021

− Potential to be the First CAR Cell Therapy Approved for Outpatient Administration